Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Abstract Text:

Bin Liu,Fraser Conrad,Audrey Roth,Daryl C Drummond,Jeff P Simko,James D Marks,Bin Liu,Fraser Conrad,Audrey Roth,Daryl C Drummond,Jeff P Simko,James D Marks,

We have used a naive human single-chain fragment variable (scFv) library as a source of random shape repertoire to directly probe the altered surface chemistry of tumor cells. We reported previously the identification of more than 90 internalizing phage monoclonal antibodies targeting prostate cancer cells, including those that are hormone refractory. In this report, we describe the conversion of a panel of those scFvs into full-length human immunoglobulins (IgGs) and show that tumor specificity is retained. We have further shown that antibodies isolated from a naive phage display library can nevertheless be of high affinity towards target tumor cells. In addition, full-length IgGs retain the functionality of parental scFvs including the ability to rapidly enter target cells through receptor-mediated endocytosis and thereby to mediate efficient and specific intracellular payload delivery to tumor cells. We have used recombinant IgGs to immunoprecipitate target antigens and analyzed their molecular composition by mass spectrometry. We have identified one target antigen as activated leukocyte cell adhesion molecule (ALCAM)/MEMD/CD166 and have further studied tissue specificity of this internalizing ALCAM epitope by immunohistochemistry. Our study shows that cell type-specific internalizing human antibody can be readily identified from a naive phage antibody display library, characterized with regards to sequence, affinity, tissue specificity, and antigen identity, and modified genetically and chemically to generate various forms of targeted therapeutics.

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Publishing Authors By Initials

B Liu,F Conrad,A Roth,DC Drummond,JP Simko,JD Marks,B Liu,F Conrad,A Roth,DC Drummond,JP Simko,JD Marks,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of molecular medicine (Berlin, Germany)

VOLUME: 85

Page Numbers: 1113-23

Journal Abbreviation: J. Mol. Med.

ISSN: 0946-2716

DAY: 7

MONTH: 06

YEAR: 2007

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9504370

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

AFFILIATION: Department of Anesthesia, University of California at San Francisco, 1001 Potrero Avenue, 3C-38, San Francisco, CA 94110, USA. liub@anesthesia.ucsf.edu

Country: Germany

AGENCY: United States NIDDK

GRANT: R21 DK066429

ACRONYM: DK

MEDLINETA: J Mol Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer Related Publications

• 5alpha-reductase: history and clinical importance.
• A novel assay for monitoring internalization of nanocarrier coupled antibodies.
• Anxiety sensitivity and auditory perception of heartbeat.
• Cannabis laws: an analysis of costs.
• Continuous participation in voluntary groups as a protective factor for the psychological well-being of adults who develop functional limitations: evidence from the national survey of families and households.
• Darkness descends with two Rabs.
• Evaluation of expression based markers for the detection of breast cancer cells.
• Genetic diversity among Botulinum Neurotoxin-producing clostridial strains.
• Granulocyte transfusions in the G-CSF era. Where do we stand?
• Histone deacetylase inhibitors selectively suppress expression of HDAC7.
• Histone deacetylase inhibitors: molecular mechanisms of action.
• Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
• Interrogational neuroimaging in counterterrorism: a "no-brainer" or a human rights hazard?
• MOSQUITOES (CULICIDAE) BITING A FISH (PERIOPHTHALMIDAE).
• Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia.
• Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
• Morbidity and cost of atopic eczema in Australia.
• One-pot terminal alkene homologation using a tandem olefin cross-metathesis/allylic carbonate reduction sequence.
• Penetrating spinal injury with wooden fragments causing cauda equina syndrome: case report and literature review.
• Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees.
• Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
• Regulation of central melanocortin signaling by interleukin-1 beta.
• Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD.
• Skin cancer: a practical guide to management.
• The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.
• The role of functional imaging in the diagnosis and management of late normal tissue injury.
• The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.
• The way of all flesh - the 21st Century.
• Updated assessment of the six-minute walk test as predictor of acute radiation-induced pneumonitis.
• Who really wants to save the apes?